News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
129,145 Results
Type
Article (4286)
Company Profile (88)
Press Release (124771)
Section
Business (42053)
Career Advice (208)
Deals (6154)
Drug Delivery (13)
Drug Development (17407)
Employer Resources (18)
FDA (1485)
Job Trends (2777)
News (66159)
Policy (3643)
Tag
2024 BioCapital Digital (2)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (5)
2024 Biotech Beach Digital (7)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (6)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (1)
2025 Lone Star Bio Digital (1)
2026 Biotech Bay Standard (1)
Academia (290)
Adcomms (1)
Allergies (16)
Alliances (11440)
ALS (26)
Alzheimer's disease (317)
Antibody-drug conjugate (ADC) (24)
Approvals (1496)
Artificial intelligence (44)
Autoimmune disease (6)
Automation (3)
Bankruptcy (38)
Best Places to Work (2248)
BIOSECURE Act (13)
Biosimilars (6)
Biotechnology (85)
Bladder cancer (19)
Brain cancer (6)
Breast cancer (61)
Cancer (504)
Cardiovascular disease (14)
Career advice (196)
Career pathing (4)
CAR-T (53)
Cell therapy (161)
Cervical cancer (6)
Clinical research (14057)
Collaboration (236)
Compensation (95)
Complete response letters (2)
COVID-19 (428)
CRISPR (7)
C-suite (92)
Cystic fibrosis (25)
Data (538)
Depression (6)
Diabetes (47)
Diagnostics (692)
Digital health (1)
Diversity, equity & inclusion (8)
Drug discovery (41)
Drug pricing (5)
Drug shortages (2)
Duchenne muscular dystrophy (20)
Earnings (12449)
Editorial (4)
Employer resources (18)
Events (24537)
Executive appointments (234)
FDA (1697)
Featured Employer (13)
Frontotemporal dementia (5)
Funding (208)
Gene editing (20)
Generative AI (4)
Gene therapy (76)
GLP-1 (106)
Government (340)
Guidances (8)
Healthcare (1522)
Huntington's disease (6)
IgA nephropathy (5)
Immunology and inflammation (22)
Indications (9)
Infectious disease (454)
Inflammatory bowel disease (50)
Inflation Reduction Act (1)
Influenza (16)
Intellectual property (32)
Interviews (17)
IPO (2926)
IRA (4)
Job creations (665)
Job search strategy (184)
Kidney cancer (1)
Labor market (7)
Layoffs (37)
Legal (638)
Liver cancer (12)
Lung cancer (39)
Lymphoma (43)
Management (4)
Manufacturing (74)
MASH (9)
Medical device (397)
Medtech (397)
Mergers & acquisitions (3404)
Metabolic disorders (109)
Multiple sclerosis (20)
NASH (1)
Neurodegenerative disease (15)
Neuropsychiatric disorders (3)
Neuroscience (429)
NextGen: Class of 2025 (857)
Non-profit (272)
Northern California (757)
Now hiring (4)
Obesity (56)
Opinion (37)
Ovarian cancer (29)
Pain (19)
Pancreatic cancer (19)
Parkinson's disease (34)
Partnered (4)
Patents (50)
Patient recruitment (26)
Peanut (12)
People (16367)
Pharmaceutical (8)
Phase I (5579)
Phase II (6710)
Phase III (3443)
Pipeline (272)
Podcasts (2)
Policy (23)
Postmarket research (209)
Preclinical (2387)
Press Release (51)
Prostate cancer (18)
Psychedelics (2)
Radiopharmaceuticals (46)
Rare diseases (62)
Real estate (1442)
Recruiting (10)
Regulatory (2939)
Reports (13)
Research institute (297)
Resumes & cover letters (20)
RSV (4)
Schizophrenia (12)
Series A (38)
Series B (28)
Service/supplier (2)
Sickle cell disease (10)
Southern California (690)
Special edition (1)
Spinal muscular atrophy (36)
Sponsored (4)
Startups (983)
State (1)
Stomach cancer (2)
Supply chain (13)
The Weekly (2)
United States (5740)
Vaccines (73)
Venture capitalists (7)
Webinars (6)
Weight loss (20)
Women's health (4)
Worklife (2)
Date
Today (26)
Last 7 days (179)
Last 30 days (695)
Last 365 days (8906)
2025 (2075)
2024 (9142)
2023 (9881)
2022 (11995)
2021 (12644)
2020 (9850)
2019 (6672)
2018 (5275)
2017 (6073)
2016 (5592)
2015 (6439)
2014 (4922)
2013 (4061)
2012 (4400)
2011 (4870)
2010 (4515)
Location
Africa (137)
Alabama (27)
Alaska (1)
Arizona (25)
Arkansas (2)
Asia (8452)
Australia (1989)
California (1738)
Canada (509)
China (100)
Colorado (29)
Connecticut (63)
Delaware (22)
Europe (18404)
Florida (161)
Georgia (23)
Idaho (10)
Illinois (119)
India (3)
Indiana (91)
Iowa (1)
Japan (30)
Kansas (11)
Kentucky (2)
Louisiana (1)
Maine (2)
Maryland (203)
Massachusetts (1260)
Michigan (65)
Minnesota (89)
Missouri (7)
Montana (8)
Nebraska (2)
Nevada (4)
New Hampshire (5)
New Jersey (387)
New Mexico (6)
New York (423)
North Carolina (252)
North Dakota (3)
Northern California (757)
Ohio (37)
Oklahoma (5)
Oregon (4)
Pennsylvania (352)
Puerto Rico (3)
Rhode Island (4)
South America (198)
South Carolina (1)
Southern California (690)
Tennessee (15)
Texas (199)
Utah (18)
Virginia (10)
Washington D.C. (7)
Washington State (302)
Wisconsin (5)
129,145 Results for "accutar biotechnology".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024
Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence -enabled drug discovery, announced data from an ongoing Phase 1 study of AC699 monotherapy in patients with ER-positive / HER2-negative locally advanced or metastatic breast cancer.
June 1, 2024
·
3 min read
Business
Evommune and Accutar Biotechnology Announce AI Drug Discovery Collaboration
Evommune, Inc. and Accutar Biotechnology Inc. today announced a new strategic partnership focused on the discovery of novel small molecule drug candidates in chronic inflammatory diseases.
November 28, 2023
·
2 min read
Drug Development
Accutar Biotechnology Announces First Patient Dosed with AC0676 in Phase 1 Study in Patients with Relapsed/Refractory B-cell Malignancies
Accutar Biotechnology, Inc. today announced the dosing of the first patient in a Phase 1 study of AC0676, an orally bioavailable, chimeric degrader molecule designed to target and degrade Bruton’s Tyrosine Kinase (BTK) with high potency, selectivity, and broad mutant coverage.
June 20, 2023
·
2 min read
Drug Development
Accutar Biotechnology Announces First Patient Dosed in China with AC0176 in Phase 1 Study in Prostate Cancer
Accutar Biotechnology, Inc announces the dosing of the first patient in China in a Phase 1 study of AC0176, an orally bioavailable chimeric degrader molecule designed to target Androgen Receptor (AR) protein with high potency and selectivity.
February 23, 2023
·
1 min read
Drug Development
Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0676 in B-cell Malignancies
Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug application (IND) for AC0676 for the treatment of patients with relapsed/refractory B-cell malignancies.
February 3, 2023
·
2 min read
Pharm Country
Accutar Biotechnology Receives NMPA Clearance of IND Application for AC0176 in Prostate Cancer
Accutar Biotechnology, Inc. , a clinical stage biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, announces that the China National Medical Products Administration (NMPA) has cleared the company’s investigational new drug application (IND) for AC0176 for the treatment of patients with metastatic Castration Resistant Prostate Cancer (mCRPC).
August 19, 2022
·
2 min read
Drug Development
Accutar Biotechnology Announces First Patient Dosed in China with AC0682 in Phase 1 Study in ER-Positive Breast Cancer
Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, announces the dosing of the first patient in China in a Phase 1 study of AC0682, an orally bioavailable chimeric degrader molecule designed to target ERα protein with high potency and selectivity.
October 11, 2022
·
1 min read
Policy
Accutar Biotechnology Receives NMPA Clearance of IND Application for AC0682 in ER-Positive Breast Cancer
Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence -empowered drug discovery, announces that the China National Medical Products Administration has cleared the company’s investigational new drug application for AC0682 for the treatment of patients with estrogen receptor -positive breast cancers.
April 1, 2022
·
1 min read
Pharm Country
Accutar Biotechnology Announces Fast Track Designation Granted by FDA to AC0176 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Accutar Biotechnology, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AC0176 for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) with disease progression on or after treatment with androgen receptor signaling inhibitors
June 1, 2022
·
2 min read
Drug Development
Accutar Biotechnology Announces First Patient Dosed with AC0176 in Phase 1 Study in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence (AI)-enabled drug discovery, today announced the dosing of the first patient in a Phase 1 study of AC0176, an orally bioavailable, chimeric degrader molecule designed to target the androgen receptor (AR) with high potency and selectivity.
March 30, 2022
·
1 min read
1 of 12,915
Next